Skip to main content

Table 4 HPA haplotypes of HPA 1–3 in patients and controls

From: Association of human platelet alloantigens encoding gene polymorphisms with the risk of Coronary artery disease in Iranian patients

Haplotypesa Frequencies Association test
HPA1 HPA2 HPA3 Hap.freq
CAD (freq)
Hap.freq Controls (freq) χ2 P valueb Pcc OR (95% CI)*
a a a 193 (0.482) 87 (0.437) 0.947 0.330597 0.910024 1.186 (0.84–1.67)
a a b 125 (0.313) 73 (0.363) 1.672 0.196024 0.729941 0.789 (0.55–1.13)
a b a 23 (0.058) 12 (0.059) 0.007 0.931565 1 0.969 (0.47–1.99)
a b b 22 (0.054) 6 (0.031) 1.639 0.200514 0.738865 1.804 (0.72–4.50)
b a a 17 (0.042) 15 (0.073) 2.743 0.097746 0.460523 0.547 (0.26–1.12)
b a b 15 (0.037) 3 (0.016) 2.023 0.155039 0.636068 2.357 (0.69–7.95)
b b a 2 (0.006) 4 (0.020)  
b b b 3 (0.008) 0 (0.000)  
  1. CAD coronary artery disease
  2. *95% confidence interval for difference between Hap.freq case–control; If a CI does not contain 0, frequencies of haplotypes in case and control groups are significantly different at α = 0.05
  3. aHPA haplotype (HPA1/HPA2/HPA3) frequency determined by the maximum likelihood method
  4. bFisher’s exact test
  5. cPc = corrected P, according to the Bonferroni method [Pc = 1 − (1 – P)n], where n = number of comparisons